Why Promising Mouse Data Isn’t a Guarantee: The 5-10% Rule in Oncology Drug Development

This is one of the most famous—and sobering—statistics in oncology drug development. Based on decades of translational research and meta-analyses, the widely cited figure is that approximately 90% to 95% of oncology drugs that show efficacy in mouse tumor models fail to be effective in humans. This means the success rate (the percentage that do work) is typically cited as being between 5% and 10%. Here is the breakdown of why this happens and the specific data behind it:

1. The “5% to 10%” Rule of Thumb

The most frequently cited study on this topic comes from a 2001 analysis by Iain W. Johnson and colleagues. They looked at the historical correlation between mouse tumor models (primarily xenografts where human tumors are implanted into immunodeficient mice) and Phase II clinical trial results in humans.

• True positive rate: They found that if a drug worked in mice, the probability it would work in humans was only about 5%.
• The catch (False positives): Mice are actually very good at predicting toxicity, but very bad at predicting efficacy.

More recent data from the National Institutes of Health (NIH) and Tufts Center for the Study of Drug Development paint a slightly more nuanced picture:

• The overall clinical approval rate for oncology drugs from Phase I to approval is about 5.3% to 6%.
• However, of the drugs that fail specifically because of lack of efficacy in Phase II or Phase III trials, a massive portion had previously shown strong anti-tumor responses in mouse models.

2. Why is “Ovation” (Promising Mouse Data) So Misleading? (The Scientific Reasons)

For a startup like XYZ Company, its KD061 program showing “>70% tumor growth inhibition in mice” is a necessary first step, but it is far from a guarantee of human efficacy. The 90-95% failure rate is due to three major biological disparities:

• The “Mickey Mouse” Tumor Problem: Standard xenograft mice have no functional immune system (they are “nude” or “SCID” mice). This means the mouse immune system doesn’t react to the human tumor, which completely ignores the role of the tumor microenvironment and immune evasion—both of which are key to solid tumor (like renal cell carcinoma) resistance in humans.
• Pharmacokinetics vs. Pharmacodynamics: A mouse liver metabolizes drugs completely differently than a human liver. A drug might achieve a high enough concentration in the mouse bloodstream to kill the tumor, but the human liver might rapidly metabolize the drug into an inactive form before it ever reaches the tumor.
• Tumor Heterogeneity: The cancer cells implanted into a mouse are typically a homogenous cell line grown in a lab for decades. Human tumors are highly heterogeneous—meaning different cells within the same tumor have different mutations. Drugs that hit one specific pathway in a mouse tumor often miss the redundant escape pathways that human tumors activate.

3. The “New Hope”

While the historical rate is 5-10%, that number is climbing for drugs with validated biomarkers. The FDA’s recent oncology approvals increasingly use a “biomarker-driven” approach. For XYZ Company specifically, its target (HIF-2alpha and ferroptosis) is highly relevant. Notably, the FDA-approved drug belzutifan (Welireg), which targets HIF-2alpha, did translate well from mice to humans for renal cell carcinoma. If XYZ Company’s KD061 indeed induces ferroptosis via a novel mechanism that bypasses standard GPX4 resistance, it may fall into a higher success bracket than the historical 5%—but it is still operating within a statistical reality where 90% of drugs fail in humans despite working in mice.

Bottom Line for Investors/Stakeholders

When you evaluate a preclinical company like XYZ Company, “efficacy in mice” is a ticket to the game, not a win. The real “Ovation” moments for XYZ Company will occur when it hits the 2026/2027 milestones:

1. IND filing (Q4 2026): Proving the drug is manufacturable and safe in toxicology studies.
2. Phase 1 human dosing (2027): Proving it is tolerable in humans.
3. Phase 2 efficacy: Showing actual tumor shrinkage in patients.

Until then, the historical data suggests a ~90-95% probability of failure that they must overcome with smart trial design and biomarker selection.

Posted in News

What is Quantitative Systems Pharmacology (QSP)?

Definition:

QSP is a sophisticated computational modeling and simulation approach that mathematically integrates:

1. Drug mechanisms of action (on-target and off-target pathways)
2. Disease pathophysiology and biological mechanisms
3. Multi-scale human biology (from molecular and cellular to organ and systemic levels)
4. Drug-biology interactions to predict how patients respond to treatment

In simpler terms: QSP uses computers to build “virtual patients” that simulate how drugs actually work in the human body across complex biological systems, accounting for how drugs bind to targets, how that triggers cascades of effects, and ultimately whether efficacy or safety issues will occur.

Core Capabilities of QSP Models

QSP can simultaneously model:

• Drug efficacy and dose-response relationships
• Drug safety (toxicity, cytokine release syndrome, bone density changes, etc.)
• Patient variability in response (why some patients respond differently)
• Dosing optimization to maximize benefit while minimizing risk
• Pediatric vs. adult differences in drug response
• Special populations (immune-competent vs. immunocompromised patients)
• Optimal dosing for complex biologics (e.g., bispecific monoclonal antibodies)

FDA’s Stance: YES – Strong Embrace (As of 2026)

Short Answer: The FDA is actively embracing and promoting QSP. This is NOT a hypothetical—it’s happening NOW.

Evidence of FDA Embrace:

1. Rapid Growth in FDA Submissions (2024 Update)

According to the FDA’s own December 2024 landscape analysis published in CPT Pharmacometrics & Systems Pharmacology:

• QSP submissions have MORE THAN DOUBLED since 2020 (when previous analysis was done)
• Number of regulatory submissions continues to increase steadily since 2013
• FDA Office of Clinical Pharmacology is actively processing and accepting QSP applications
• QSP is being submitted in both NDAs (New Drug Applications) and BLAs (Biologics License Applications)

2. BRAND NEW FDA Draft Guidance (June 2026)

MAJOR ANNOUNCEMENT: The FDA just published a draft guidance on June 24, 2026 (literally 1 month ago from your current date):

Title: “Quantitative Systems Pharmacology (QSP)-Based Dose Selection for Minimum Anticipated Biological Effect Level (MABEL) in First-in-Human (FIH) Trials”

Published: Federal Register document 2026-12619, Volume 91, page 38004 (June 24, 2026)

What This Means:

• FDA is formally endorsing QSP as an acceptable tool for determining starting doses in first-in-human clinical trials
• This is historically significant because MABEL calculations typically relied on animal studies—QSP offers an alternative
• Strategic goal stated by FDA: “Reduce reliance on animal studies” in early phase drug development
• Comments are being accepted until July 24, 2026 for the final guidance

3. Specific FDA Recommendations (From Draft Guidance):

The FDA draft guidance recommends that sponsors using QSP for MABEL:

• Develop models using reliable computational software with thoroughly documented code
• Use biologically plausible parameters based on human-derived data
• Validate models against clinical observations where available
• Perform sensitivity analyses to ensure model robustness
• Integrate knowledge of:
  • Receptor occupancy dynamics
  • Target expression levels
  • Threshold dose where biological effects begin

4. Expanding Applications Across Therapeutic Areas

As of December 2023 (latest FDA analysis), QSP submissions covered:

Therapeutic Area	Use Case
Oncology	Dose optimization, safety/efficacy balance
Immunology	Cytokine release syndrome risk assessment
Infectious Disease	Pediatric dosing, special populations
Rare Diseases	Limited patient populations, precision dosing
Cardiovascular	Drug-disease interaction modeling
Bone/Metabolic	Bone density effects, long-term safety
Inborn Errors of Metabolism	Complex biochemical pathway modeling

Key Finding: >66% of submissions focused on drug efficacy, but a growing proportion address drug safety.

5. Case Study: Bispecific Monoclonal Antibody

The FDA’s 2024 landscape report highlighted an anonymized real case demonstrating QSP’s value:

• Challenge: Bispecific mAb with risk of cytokine release syndrome (CRS)
• QSP Application: Modeled how different dosing regimens would trigger CRS at different frequencies
• Outcome: Used QSP to optimize dosing to minimize CRS risk while maintaining efficacy
• FDA Result: Accepted the QSP-based dosing recommendation

This demonstrates that FDA is actually using QSP to make regulatory decisions, not just accepting it for information.

6. Pediatric Applications

QSP submissions have increasingly been used to simulate and compare treatment responses between pediatric and adult populations, helping justify dosing differences without extensive pediatric trials—a huge advantage for rare disease development.

Why FDA is Embracing QSP

Strategic Rationale:

1. Reduces Animal Testing: Aligns with FDA’s broader “3Rs” initiative (Replace, Reduce, Refine animal studies)
2. Accelerates Drug Development: Better starting doses = safer, faster dose escalation
3. Improves Safety: Simultaneous modeling of efficacy and toxicity reduces surprises in trials
4. Precision Medicine: Enables patient-specific predictions and identifies responder populations
5. Rare Diseases: Enables development in small populations without large animal studies
6. Special Populations: Better modeling of pediatric, geriatric, hepatic/renal impairment patients

Current Limitations & Challenges

FDA Also Recognizes:

1. Model Credibility: Not all QSP models are equally valid—requires rigorous validation
2. Data Quality: Models are only as good as their input data (human-derived data preferred over animal data)
3. Standardization: Need for standardized approaches to QSP development and reporting
4. Expertise: Requires sophisticated computational and biological expertise
5. Transparency: Code documentation and model assumptions must be clearly disclosed (ALCOA principles)

Comparison: FDA vs. EMA Stance

Notably: Both the FDA and EMA are converging on accepting QSP as a legitimate regulatory tool. The EMA has similarly advanced their positions on model-informed drug development.

Bottom Line

Will FDA Embrace QSP?

Answer: YES—it already is.

• ✓ QSP submissions have more than doubled in the past 4 years
• ✓ Brand new draft guidance just published (June 2026) specifically endorsing QSP for MABEL dose selection
• ✓ FDA is actively making regulatory decisions based on QSP models
• ✓ Strategic FDA priority is to expand and standardize QSP use
• ✓ Guidance covers first-in-human dosing, pediatric development, safety assessment, and rare diseases
• ✓ 11 public comments received on the June 2026 guidance (showing industry engagement)

The FDA isn’t just accepting QSP—they’re actively promoting it as a preferred method over traditional animal-based approaches for certain applications, particularly first-in-human dose selection and special population dosing.

If you’re involved in drug development, QSP is transitioning from “nice-to-have” to increasingly essential for competitive advantage and streamlined regulatory review, especially for:

• Complex biologics
• Rare diseases
• Pediatric formulations
• Drugs with narrow therapeutic windows

The June 2026 guidance will likely become the final standard within the next 12-18 months, setting the expectations for how QSP should be implemented in regulatory submissions going forward.

Posted in News